Cas No.: | 869886-67-9 |
Chemical Name: | Ulixertinib (BVD-523) |
Synonyms: | BVD-523, BVD 523, BVD523, VRT752271, VRT752271, VRT 752271, Ulixertinib |
SMILES: | N1C(C(=O)N[C@H](CO)C2C=C(Cl)C=CC=2)=CC(C2=CC(NC(C)C)=NC=C2Cl)=C1.Cl |
Formula: | C21H22Cl2N4O2 |
M.Wt: | 433.33 |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | Ulixertinib (VRT752271) is a reversible, ATP-competitive inhibitor of ERK1 and ERK2 kinases, with IC50 of <0.3 nM against ERK2. |
In Vivo: | In the pharmacokinetic study, the sensitivity and specificity of the assay are found to be sufficient for accurately characterizing the plasma pharmacokinetics of Ulixertinib in Balb/C mice[1]. |
In Vitro: | Ulixertinib (VRT752271) is a reversible, ATP-competitive inhibitor of ERK1 and ERK2 kinases, with IC50 of <0.3 nM against ERK2[2]. |